Biotech of the Week: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals (ANIP 0.79%) is the biotech of the week on the Fool's weekly show Biotech Banter. Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went public last year through a merger with BioSante.

Since then the company acquired some already-approved generic drugs from Teva Pharmaceuticals (TEVA 1.01%) and set up partnerships with Sofgen Pharmaceuticals and Sterling Pharmaceutical Services.

In addition to sales of its generic-drug products, ANI Pharmaceuticals has potential for milestones and royalties from BioSante's legacy programs: a testosterone gel licensed to Teva and a portfolio of cancer vaccines licensed to Aduro BioTech.

The small generic-drug maker might have trouble competing with Teva, Novartis (NVS 2.27%), and the rest of the big boys, but ANI Pharmaceuticals may be able to find a niche and potentially be a takeout target down the road.